Drugs / Commercial Hepatitis B vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03038802 Comparator | Mar 2026 → Mar 2027 expected | chronic hepatitis B virus infection | Vaxine Pty Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Commercial Hepatitis B vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03038802 ↗ |
| Modality | Vaccine | “Commercially available prophylactic hepatitis B vaccine” NCT03038802 ↗ |
| Route | Intramuscular | “regular intramuscular injections of a commercial hepatitis B vaccine” NCT03038802 ↗ |